Introduction and comparison of alternative and optimization methods for quality-adjusted life-year in health value assessmentHU Hong-fei, ZHOU Ting, LI Feng, MA Ai-xia1969-1975
Research on the quality control and development strategy of continuous manufacturing of chemical oral solid preparationsLI Xiang-yu, LIN Xiao-feng, LAN Yi-peng, HUANG Zhe1976-1981
Analysis of the overall characteristics of patent invalidation request activities in the pharmaceutical industryLI Yan, ZHU Xue-zhong1982-1989
Research on the influence of marketing authorization holder system on pharmaceutical industry innovationHE Feng, WAN Pai-jie, PI Zhi-peng, AN Shu-han, WU Rengaowa1990-1997
Experience of the U.S.FDA clinical outcome assessment qualification and its enlightenment for ChinaWU Ya-nan, SHI Zhao, LI Shun-ping1998-2004
Inclisiran:a new small interfering RNA drug for the treatment of hypercholestermiaJI Ya-chun, QI Jun-sheng2013-2022
Mechanism and clinical evaluation of a novel drug nedosiran for the treatment of primary hyperoxaluria type 1DU Wen-lin, LUO Chun-mei, WU Xiao-yan, ZHANG Rong2023-2027
General considerations on the pharmaceutical research in the development of enteric coated generic formulations for proton pump inhibitorsZHANG Bao-mei, CHEN Hui, LU Xiao-jun2028-2032
Polyethylene glycol-related histopathological changes and evaluation considerations in nonclinical studies of polyethylene glycol-modified drugsRONG Yi, LI Hao-yun, LI De-li, DONG Tian-tian, MENG Li-kai, GONG Xin-jiang, ZHANG Hui, YAN Li-ping2033-2037